Results 161 to 170 of about 25,017 (220)

Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332_gp120 glycan-independent epitope. [PDF]

Nat Immunol
Gieselmann L, DeLaitsch AT, Rohde M, Radford C, Worczinski J, Ashurov A, Ahmadov E, Burger JA, Havenar-Daughton C, Deshpande S, Giovannoni F, Corti D, Kreer C, Ercanoglu MS, Schommers P, Georgiev IS, West AP, Knüfer J, Stumpf R, Kroidl A, Geldmacher C, Maganga L, William W, Ntinginya NE, Hoelscher M, Yang Z, Wei Q, Renfrow MB, Green TJ, Novak J, van Gils MJ, Gristick HB, Gruell H, Bloom JD, Seaman MS, Bjorkman PJ, Klein F.   +36 more
europepmc   +1 more source

Inhibition of CD4+ T-cell function by the HIV envelope protein, gp120.

Disease markers, 1990
openaire   +1 more source

Host Glycan-Lectin Interplay in SARS-CoV-2 Infection. [PDF]

Int J Mol Sci
Oh H, Thi Thuy Tien V, Ahmed S, Choi J, Ryu KJ, Yang J.   +5 more
europepmc   +1 more source

Selective capture and digital counting of intact HIV pseudovirus using designer DNA nets, tethered motion, and photonic resonator interferometric scattering microscopy. [PDF]

APL Bioeng
Tibbs J, Umrao S, Song T, Anirudhan V, Shepherd S, Wolhaupter K, Zheng M, Wiggins S, Rong L, Hisey CL, Demirci U, Wang X, Cunningham BT.   +12 more
europepmc   +1 more source

Stoichiometry of HIV-1 envelope glycoprotein protomers with changes that stabilize or destabilize the pretriggered conformation. [PDF]

mBio
Zhang Z, Anang S, Wang Q, Nguyen HT, Chen H-C, Chiu T-J, Yang D, Smith AB, Sodroski JG.   +8 more
europepmc   +1 more source

Advancements in development of novel class of HIV protease inhibitors. [PDF]

Ann Med
Gu WG, Yin GZ, Zhang YP.
europepmc   +1 more source

Multi-attribute monitoring (MAM) methodology for glycosylated subunit vaccines. [PDF]

Sci Rep
Shajahan A, Jenkins LM, Barefoot N, Maldonado D, Wolff JJ, Yang Y, Kueltzo LA, Ficca V, Scheideman E, Loukinov I, Carruthers C, Benmohamed D, Gowetski DB, Jiang R, Yang SR, Carlton K, Gall JG, Lei QP.   +17 more
europepmc   +1 more source

Rapidly acquired HIV-1 neutralization breadth in a rhesus V2 apex knockin mouse model after a single bolus immunization. [PDF]

Sci Immunol
Ghosh AR, Habib R, Mishra N, Roark RS, Akauliya M, Albowaidey AA, Allen JD, Amereh K, Avillion G, Bottermann M, Liang B, Chaudhary N, Callaghan S, Dye J, Li X, Ellis-Pugh JR, Roy Chowdhury R, James NE, Liu X, Maiorino L, Villavicencio PM, Nedellec R, Oberoi P, Sowers KJ, Park Y, Prum T, Rodriguez L, Ssozi M, Torres JL, Walsh AA, Warner JE, Weldon SR, Xu L, Wiehe K, Crispin M, Ward AB, Nair U, Hahn BH, Burton DR, Shapiro L, Kwong PD, Irvine DJ, Andrabi R, Shaw GM, Batista FD.   +44 more
europepmc   +1 more source

J3ExoA: A Novel Anti-HIV Immunotoxin Fusion of Anti-Gp120 J3VHH and PE38 Fragment of <i>Pseudomonas</i> Exotoxin A. [PDF]

Pharmaceuticals (Basel)
Pincus SH, Luo K, Peters T, Gordy JT, Cole FM, Klug G, Ober K, Marcotte TK, Markham RB.   +8 more
europepmc   +1 more source

Heterologous combinations of VSV-GP and native-like trimers elicit autologous Tier 2 HIV antibodies in rabbits. [PDF]

NPJ Vaccines
Radvan F, Hauser A, Lin LY, Wilmschen-Tober S, Schaber M, Bermejo-Jambrina M, Agbabiaka TO, Peterhoff D, Riepler L, Mendrzyk N, Beierfuß A, Speth C, Moog C, von Laer D, Wagner R, Kimpel J.   +15 more
europepmc   +1 more source